相关实验视频

Updated: May 28, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

用低剂量德西他与重组人体血栓形成素或埃尔特罗姆波巴格结合治疗的耐药性免疫血栓缩症:两例病例报告

Yuxia Jiang¹, Yani Xu², Haiying Wu¹

¹Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.

|February 10, 2025

概括

低剂量德平与血栓形成素或ELTROMBOPAG相结合,对治疗耐药性免疫血栓缩症 (ITP) 显示出有前途. 这种组合治疗有效地增加了两个患者的血小板计数,提供了潜在的新治疗途径.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫性血小板缺血 (ITP) 是一种自身免疫性疾病,其特征是血小板破坏和血小板生产减少.
耐火性ITP是一个重大的治疗挑战,需要新的治疗策略.

研究的目的:

评估低剂量德西因与血栓形成素或ELTROMBOPAG结合治疗耐火性ITP的疗效.

主要方法:

两名耐火性ITP患者的病例报告.
治疗涉及低剂量西结合复合人体血栓形成素或eltrombopag.

主要成果:

两位患者在组合治疗后都实现了正常的血小板计数.
该疗法在血小板数恢复方面表现出积极的反应.

结论:

低剂量德西他与血栓形成素或埃尔特罗姆波巴格结合可能在治疗耐火性ITP方面具有协同效应.
这种组合疗法代表了难以治疗的ITP患者的潜在治疗选择.

更多相关视频

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...